Lemaitre Vascular (LMAT) Current Deferred Revenue (2018 - 2019)
Lemaitre Vascular's (LMAT) quarterly Current Deferred Revenue came in at $188000.0 in Q2 2019, down 80.23% year-over-year from $951000.0 in Q2 2018, and down 48.91% quarter-over-quarter from $368000.0 in Q1 2019.
Powered by 
Analysis
Lemaitre Vascular (LMAT) Current Deferred Revenue (2018 - 2019) Analysis & Trends
Lemaitre Vascular (LMAT) has reported Current Deferred Revenue for 2 consecutive years, with $188000.0 the latest figure, recorded in Q2 2019.
- On a quarterly basis, Current Deferred Revenue fell 80.23% year-over-year to $188000.0 in Q2 2019; TTM through Jun 2019 was $188000.0, a 80.23% decrease from a year earlier, with the FY2018 full-year figure at $552000.0, changed N/A from the prior year.
- Current Deferred Revenue was $188000.0 for Q2 2019 at Lemaitre Vascular, down from $368000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $951000.0 in Q2 2018 and troughed at $188000.0 in Q2 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn |
| 10 | Lemaitre Vascular | 1.80 Bn | 1.43 Bn | 50.76 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2019 | 188,000.00 |
| Mar 31, 2019 | 368,000.00 |
| Dec 31, 2018 | 552,000.00 |
| Sep 30, 2018 | 752,000.00 |
| Jun 30, 2018 | 951,000.00 |